Literature DB >> 12143898

Arthrogryposis multiplex congenita.

P O'Flaherty1.   

Abstract

Arthrogryposis multiplex congenita (AMC) is a term that is used to describe the presence of multiple joint contractures at birth. AMC can be seen singularly or in conjunction with other abnormalities. Historically, the term arthrogryposis was used as a disease diagnosis, but it is now clear that AMC is not a disease entity but a syndrome, involving a manifestation of many fetal and neonatal disorders of the neuromuscular system. Its etiology is multifocal, and there is a wide variation in the degree to which muscles and joints are affected. Early identification and implementation of a plan of therapy are essential. The purpose of this article is to provide an overview of the AMC 'syndrome, specifically, clinical features, etiology, diagnosis, therapeutic interventions, family support, and outcomes.

Entities:  

Mesh:

Year:  2001        PMID: 12143898     DOI: 10.1891/0730-0832.20.4.13

Source DB:  PubMed          Journal:  Neonatal Netw        ISSN: 0730-0832


  4 in total

1.  A Novel Variant in the Endothelin-Converting Enzyme-Like 1 (ECEL1) Gene in an Emirati Child.

Authors:  Abdul Rezzak Hamzeh; Pratibha Nair; Madiha Mohamed; Fatima Saif; Nafisa Tawfiq; Mohamed Khalifa; Mahmoud Taleb Al-Ali; Fatma Bastaki
Journal:  Med Princ Pract       Date:  2017-01-18       Impact factor: 1.927

2.  A Danish population-based twin study on autism spectrum disorders.

Authors:  Claudia Nordenbæk; Meta Jørgensen; Kirsten Ohm Kyvik; Niels Bilenberg
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-05-10       Impact factor: 4.785

3.  Arthrogryposis Multiplex Congenita: Multiple Congenital Joint Contractures.

Authors:  Hamza Sucuoglu; Nurettin Irem Ornek; Cagkan Caglar
Journal:  Case Rep Med       Date:  2015-10-28

4.  Genetic diagnosis and clinical evaluation of severe fetal akinesia syndrome.

Authors:  Theresa Reischer; Sandra Liebmann-Reindl; Dieter Bettelheim; Sukirthini Balendran-Braun; Berthold Streubel
Journal:  Prenat Diagn       Date:  2020-09-10       Impact factor: 3.050

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.